| IGF2BP3 siRNA (Human) | |
| Description | siRNA to inhibit IGF2BP3 expression using RNA interference |
| Specificity | IGF2BP3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression. |
| Form | Lyophilized powder |
| Gene Symbol | IGF2BP3 |
| Alternative Names | IMP3; KOC1; VICKZ3; Insulin-like growth factor 2 mRNA-binding protein 3; IGF2 mRNA-binding protein 3; IMP-3; IGF-II mRNA-binding protein 3; KH domain-containing protein overexpressed in cancer; hKOC; VICKZ family member 3 |
| Entrez Gene (Human) | 10643 |
| SwissProt (Human) | O00425 |
| Purity | > 97% |
| Storage/Stability | Shipped at 4 °C. Store at -20 °C for one year. |
| Pack Size | 15 nmol | 30 nmol |
IGF2BP3 siRNA (Human)
| Catalogue No | BSRH-7253 |
| Source | Synthetic |
| Reactivity | Human |
| Applications | RNAi |
| Price | POR |
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
We recommends transfection with 10 nM - 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For example, resuspend one tube of 5 nmol siRNA oligo in 250 μl of DEPC water to get a final concentration of 20 μM.